Biotechnology

INOVIO Planning for ex-US Global Phase 3 Trial for INO-4800

Given universal eligibility and broad availability of COVID-19 vaccines in the U.S., DoD JPEO-CBRND has notified INOVIO that it will discontinue funding for the Phase 3 INO-4800 trial INOVIO adjusts INO-4800 clinical development strategy to focus on global unmet COVID-19 vaccine needs PLYMOUTH ...

2021-04-23 20:00 5656

The NDA of the Novel Anti-PD-1 mAb Serplulimab of Henlius Accepted by NMPA and Proposed to be Granted Priority Review

SHANGHAI, April 23, 2021 /PRNewswire/ -- Shanghai Henlius Biotech, Inc. (2696.HK) announced that the New Drug Application (NDA) of serplulimab injection (HLX10), a novel anti-PD-1 monoclonal antibody (mAb), for the treatment of unresectable or metastatic microsatellite instability-high (MSI-H) s...

2021-04-23 15:00 2593

The NDA of the Novel Anti-PD-1 mAb Serplulimab of Henlius Accepted by NMPA and Proposed to be Granted Priority Review

SHANGHAI, April 22, 2021 /PRNewswire/ -- Shanghai Henlius Biotech, Inc. (2696.HK) announced that the New Drug Application (NDA) of serplulimab injection (HLX10), a novel anti-PD-1 monoclonal antibody (mAb), for the treatment of unresectable or metastatic microsatellite instability-high (MSI-H) s...

2021-04-22 21:47 4164

Wuxi Strives to Build a World-class Biomedical Industry Chain

WUXI, China, April 22, 2021 /PRNewswire/ -- From April 21 to 23, the 2021 Taihu Bay Future Healthcare Conference was held in Wuxi,China. More than 160 experts including Hejie, Fan Chunhai and many other academicians carried out forward-looking, authoritative, and predictive exchanges and dialogue...

2021-04-22 19:06 1381

RDIF and Minapharm agree to produce over 40 million doses of the Sputnik V vaccine in Egypt

MOSCOW, CAIRO and BERLIN, April 22, 2021 /PRNewswire/ -- The Russian Direct Investment Fund (RDIF,Russia's sovereign wealth fund), Egypt's Minapharm, the regional leader in recombinant DNA technology, and itsBerlin-based subsidiary, ProBioGen AG, announce the agreement to produce over 40 million ...

2021-04-22 16:00 3625

Clarivate Releases Predictive Analytics to Help Fuel Life Sciences Deal Making Landscape

Cortellis Deals Intelligence features new trends visualizations and predictive analytics supported by artificial intelligence  LONDON, April 22, 2021 /PRNewswire/ -- Clarivate Plc (NYSE: CLVT), a global leader in providing trusted information and insights to accelerate the pace of innovation, t...

2021-04-22 16:00 3966

endpoint Launches ConnectionPOINT™ - A partnership program designed to power accelerated outcomes and move medicine through next-generation eClinical technology interfacing

SAN FRANCISCO, April 21, 2021 /PRNewswire/ -- endpoint Clinical, the leading global interactive response technology (IRT®) company, announced today the launch of their partnership program,ConnectionPOINT™, the first of its kind in the eClinical technology space.  The program's vision is for a g...

2021-04-21 21:00 3957

ATH434 protects brain cells and improves motor function in Parkinsonian disorder

MELBOURNE, Australia , April 21, 2021 /PRNewswire/ -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company") today announced an oral presentation of expanded animal data to support the commercialisation of its lead compound ATH434 in clinical development for the treatment of...

2021-04-21 20:11 3002

Seed Health Closes $40 Million in Series A Financing to Launch New Categories, Accelerate Global Distribution and Expand Clinical Research

LOS ANGELES, April 21, 2021 /PRNewswire/ -- Seed Health, a microbial sciences company developing next-generation probiotic applications and live biotherapeutics, today announced the close of a $40 million Series A financing led by impact investor,The Craftory, alongside TechBio investor ARTIS Ven...

2021-04-21 20:00 1780

Seed Health Closes $40 Million in Series A Financing to Launch New Categories, Accelerate Global Distribution and Expand Clinical Research

LOS ANGELES, April 21, 2021 /PRNewswire/ -- Seed Health, a microbial sciences company developing next-generation probiotic applications and live biotherapeutics, today announced the close of a $40 million Series A financing led by impact investor,The Craftory, alongside TechBio investor ARTIS Ven...

2021-04-21 20:00 3165

Samsung Biologics Celebrates Its 10th Anniversary with Its Mission, "Driven. For Life."

INCHEON, South Korea, April 21, 2021 /PRNewswire/ -- Samsung Biologics, the world's leading contract development and manufacturing organization, celebrated the 10th anniversary of its founding today at its global headquarters in Songdo, Incheon via a virtual ceremony.

2021-04-21 19:00 2073

GenScript ProBio Enters Collaboration with Singapore's Experimental Drug Development Centre to Develop Anti-Fibrosis Therapeutic Antibody Programme

SINGAPORE, April 21, 2021 /PRNewswire/ -- GenScript Biotech Corporation (Stock Code: 1548.HK)'s biopharmaceutical CDMO segment, GenScript ProBio announced a collaboration with the Experimental Drug Development Centre (EDDC),Singapore's national platform for drug discovery and development, on an a...

2021-04-21 11:08 5745

Ascentage Pharma to Announce Results from Four Clinical Studies at 2021 ASCO Annual Meeting, with Data of Its Drug Candidates Including Lisaftoclax (APG-2575) to Be Released in Oral Presentations for the First Time

SUZHOU, China and ROCKVILLE, Md., April 21, 2021 /PRNewswire/ -- Ascentage Pharma (6855.HK), a globally focused, clinical-stage biotechnology company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced that results from four clin...

2021-04-21 08:38 3218

China Biologic Announces Completion of Going Private Transaction

BEIJING, April 20, 2021 /PRNewswire/ -- China Biologic Products Holdings, Inc. (NASDAQ: CBPO, "China Biologic" or the "Company"), a leading fully integrated plasma-based biopharmaceutical company inChina, today announced the completion of its merger (the "Merger") with CBPO Group Limited ("Merger...

2021-04-21 04:30 5888

Transcenta Received IND Clearance from US FDA for Initiating Phase I Clinical Trial for its Bi-functional Anti-PD-L1/TGF-β Antibody TST005

SUZHOU, China, April 20, 2021 /PRNewswire/ -- Transcenta Holding Limited (Transcenta), a clinical stage global biotherapeutics company with fully-integrated capabilities in discovery, development and manufacturing of antibody-based therapeutics, today announced that it has received clearance of i...

2021-04-20 20:54 1356

Biovaxys And The World Ovarian Cancer Coalition Join Forces For May 8th, World Ovarian Cancer Day

VANCOUVER, BC and TORONTO, April 20, 2021 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTC: LMNGF) ("BioVaxys"), the world leader in haptenized antigen vaccines for antiviral and cancers applications, announced today its sponsorship of this year's World Ovarian Cancer Day, a ...

2021-04-20 20:00 4672

Prenetics Signs Multi-million Dollar Collaboration with Oxford University for Advanced Molecular Diagnostics

* The collaboration is a 3-year joint effort by Prenetics R&D Team, Oxford University and Oxford Suzhou for Advanced Research (OSCAR) for Molecular Diagnostics * A new Prenetics Innovation Technology Centre is established for advanced molecular diagnostics * Collaboration follows successful...

2021-04-20 09:00 2169

AACR 2021-ImmVira presents the preclinical study results of MVR-T3011 via intravenous administration

SHENZHEN, China, April 19, 2021 /PRNewswire/ -- On April 15, 2021, ImmVira presents the preclinical study results of MVR-T3011 via intravenous administration through publication in a virtual poster at the AACR annual meeting. MVR-T3011 is a replication competent and genetically modified oncolyti...

2021-04-20 08:30 2076

Terumo Blood and Cell Technologies and CSL Plasma Announce Collaboration to Deliver New Plasma Collection Platform

LAKEWOOD, Colo. and BOCA RATON, Fla., April 19, 2021 /PRNewswire/ -- Terumo Blood and Cell Technologies and CSL Plasma today announce a collaboration to deliver a new plasma collection platform at CSL Plasma U.S. collection centers. A clinical trial of the investigational plasmapheresis device ...

2021-04-20 05:00 2667

Himalaya Therapeutics Announces Appointment of Nicholas Desjardins as Chief Financial Officer

SAN DIEGO, April 20, 2021 /PRNewswire/ -- Himalaya Therapeutics ("Himalaya"), a clinical-stage biopharmaceutical company focused on development and commercialization inGreater China of a novel class of investigational antibody therapeutics for the treatment of solid tumor cancer, which are based ...

2021-04-20 01:42 2750
1 ... 334335336337338339340 ... 345

Week's Top Stories